New immune cell therapy tested for devastating muscle disease
NCT ID NCT06371040
Summary
This early-stage study is testing a new type of treatment called CD19-BCMA CAR-T therapy for adults with severe, treatment-resistant myasthenia gravis (MG). The main goals are to see if the treatment is safe and to find the best dose. Researchers will track side effects and check if the therapy helps improve patients' daily activities and muscle weakness over 24 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospital, The Fourth Military Medical University
RECRUITINGXi'an, Shaanxi, 710038, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.